Hassan Lukman Ali

Hassan Lukman Ali

Auto-generated profile, based on publicly available information

Hassan Lukman Ali

Department of Pharmaceutical and Medicinal Chemistry, Ahmadu Bello University, Zaria, Nigeria

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in Journal of Drug Design and Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
DAUDA GARBADAUDA GARBA
DAUDA GARBA
YJYusuf Jimoh
Yusuf Jimoh
AAAkande Amatul-Hafeez
Akande Amatul-Hafeez
HAHassan Lukman Ali
Hassan Lukman Ali
MYmuhammad shamsudeen yakubu
muhammad shamsudeen yakubu
AOAkeem Ayodele Olaiya
Akeem Ayodele Olaiya
Malaria continues to be one of the most devastating global health problems due to the high morbidity and mortality it causes in endemic regions. The search for new antimalarial targets is vital because of the increasing prevalence of drug resistance in malaria parasites. Malarial proteases constitute promising therapeutic targets as they play important roles in the parasite life cycle. The inhibition of these enzymes has pharmacological and therapeutic significance since they are involved in numerous processes, including the development, invasion, egress, and breakdown of host hemoglobin to release amino acids for parasite sustenance. In this study, in silico techniques were used to shed light on the mechanisms underlying the inhibitory effects of prenylated quercetin isolated from Globimetula oreophila on plasmepsin I and II, falciparum 2 and 3, Plasmodium falciparum calcium-dependent protein kinase 2, dihydrofolate reductase-thymidylate synthase, and serine repeat antigen 5. The test compound significantly interacts with key enzyme binding pockets through hydrogen bonds, van der Waals, and hydrophobic interactions, influencing protease specificity control. Crucial ligand features like carbonyl and hydroxyl groups were identified as essential for receptor interactions. Comparative analysis revealed the test compound's strong binding affinities with energies ranging from -6.4 Kcal/mol to -9.4 Kcal/mol, indicating competitive potential against various enzymes, particularly excelling against PfDHFR-TS, plasmepsin-I, and SERA5 compared to native ligands. This suggests the compound's ability to competitively inhibit enzyme activity by targeting co-factor binding sites, especially with specific proteases, holding promise for therapeutic applications as potent inhibitors for the prevention and treatment of malaria.